AnaptysBio (ANAB) has drawn fresh attention after reporting a profitable fourth quarter and a sharply smaller full year loss, helped by collaboration revenues, milestone payments, and higher royalties ...
CEO Daniel Faga outlined progress on the company’s planned separation into two entities, provided an update on its royalty streams and ongoing litigation related to GSK’s Jemperli, and discussed the c ...
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Applovin Corp (Symbol: APP), where a total volume of 58,522 contracts has been ...
Multiple analysts have issued price targets for $ANAB recently. We have seen 6 analysts offer price targets for $ANAB in the last 6 months, with a median target of ...
AnaptysBio Inc. (NASDAQ: ANAB) has pushed back against claims that it breached its long-standing licensing deal tied to the cancer drug Jemperli, asking a Delaware court to dismiss what it calls an ...
Investigational rosnilimab was safe and well-tolerated; however, it did not meet the primary endpoint of the mean change from baseline in the modified Mayo Score (severity of ulcerative colitis, mMS) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results